Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research
Toxins · 23.04.2025 · 17 (5) · 211
DOI: 10.3390/toxins17050211 ↗Kurz gefasst
Scoping Review in der Zeitschrift Toxins, online erschienen am 23.04.2025. Verfasst von Ekene Enemchukwu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Stanford School of Medicine, Palo Alto, CA 94304, USA. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health, National Institute of Diabetes.
Abstract (Originalsprache)
Introduction and Objectives: Onabotulinum toxin A (BTXA) is an effective treatment for refractory idiopathic overactive bladder (iOAB). Given the wide spectrum of patient factors and combination of symptoms, a tailored approach to management is needed. This scoping review assesses injection paradigms for iOAB. Prior studies have established the safety and efficacy of BTXA injections, and this review focuses on exploring variations in injection techniques that may inform more tailored approaches and support future research toward optimizing patient outcomes.
Methods
We conducted a systematic literature search. Inclusion criteria included full-text English language and primary research studies assessing outcomes in adults undergoing BTXA for iOAB. Findings are summarized using narrative synthesis.
Results
Forty-three articles were identified. Key findings include fewer injections (1–10 vs. 20–40) maintains efficacy while reducing procedure time, discomfort, and retreatment hesitancy. Durability appears to be lower with suburothelial and bladder base injections and higher with detrusor and bladder body injections, though these may carry an increased risk of urinary retention requiring clean intermittent catheterization. Trigone inclusion appears safe and effective without increased vesicoureteral reflux risk.
Conclusions
Study heterogeneity and inconsistent reporting limit strong conclusions. Included injection paradigms demonstrated efficacy, high tolerability, symptom relief, and quality-of-life improvements with few adverse events. Further research is needed to refine optimal injection strategies to enhance patient comfort, maximize efficacy, and minimize adverse events. Future studies should ensure comprehensive data collection to clarify these associations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Stanford School of Medicine, Palo Alto, CA 94304, USA.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S1A1, Canada.
- Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
- Department of Urology, Atrium Health-Carolinas Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
ORCID-Profile: Ekene Enemchukwu, Raveen Syan, Michael Kennelly
Förderung
- NIDDK NIH HHS
- National Institutes of Health
- National Institute of Diabetes
- Digestive and Kidney Diseases
Zitieren
APA
Enemchukwu, E., Mohamud, H., Sinclair, S., Harbour, V., Syan, R., Kennelly, M., & Gunamany, S. (2025). Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research. Toxins, 17(5), 211. https://doi.org/10.3390/toxins17050211
Vancouver
Enemchukwu E, Mohamud H, Sinclair S, Harbour V, Syan R, Kennelly M, et al. Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research. Toxins. 2025;17(5):211. doi:10.3390/toxins17050211
BibTeX
@article{Enemchukwu2025,
author = {Enemchukwu, Ekene and Mohamud, Hodan and Sinclair, Shada and Harbour, Victoria and Syan, Raveen and Kennelly, Michael and Gunamany, Susanna},
title = {Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research},
journal = {Toxins},
year = {2025},
volume = {17},
number = {5},
pages = {211},
doi = {10.3390/toxins17050211}
}
EUVIMED